降纤酶与尿激酶治疗急性脑梗塞的临床对照研究

The controlled study on efficacy of ancord and urokinase in patients with acute cerebral infarction

目的 观察降纤酶 (Ancord)尿激酶 (UK)治疗急性脑梗塞的疗效 ,并进行临床对照研究以证明哪种药物更值得推荐。方法 将符合标准的 6 5例患者随机分为两组 ,一组接受Ancord治疗 ,另一组应用UK ,两组患者均于治疗前治疗后第 1、2、3、7、14、30天进行NIHSS评分 ;治疗前、第 1天、第 3天检测出血时间 (BT)凝血时间 (CT)、血小计数 (PLT)、凝血酶原时间 (PT)、血浆纤维蛋白原 (FIB) ;治疗后第 1、3、30天后复查头颅CT或MRI。结果 Ancord治疗组和UK治疗组NIHSS评分的统计结果未显示显著性差异 (P >0 .0 5 ) ;Ancord治疗组在用药前后BT、CT、PLT、PT均无明显变化 ,而UK治疗组在用药前后BT、CT、PLT、PT有较大变化 ,统计结果显示有显著性差异 (P <0 .0 5 ) ;Ancord治疗组并发发脑出血 2例 (6 .1% ) ,UK治疗组 4例 (12 .5 % )。结论 应用Ancord或UK治疗急性脑梗塞疗效相似 ,但Ancord治疗急性脑梗塞不影响凝血功能 ,并发脑出血少 ,在临床上更值得推荐。

Objective To observe the thereapeutic efficacy of ancord and urokinase in patients with acute cerebral infarction by means of the controlled study. So we could testify which kind of medicine was recommendable. Methods 65 patients with acute cerebral infantion were randomly divided into two groups. One group was given ancord treatment and the other was given urokinase treatment. NHISS socres were counted before and after treatment. In addition, BT、CT、PT、PLT、FIB and CT or MRI were tested at the same time. Results The NIHSS score of ancard and urokinase treatment group was similar ( P >0. 05), but BT、CT、PT、PLT greatly changed before and after treatment with urokinase compared with ancord treatment group ( P >0. 05). Meanwhile there were 2 cases (6.1%) with hemorrhage complication in ancord treatment group, 4 cases (12.5%) in urokinase treatmcnt group. Conclusions The efficacy of ancord without obvious differences compared with urokinase treatment in acute cerebral infarction, but urokinase treament largely impacted the coagulative function in comparison to ancord treatmtnt. On the whole, we predict that ancord was better than urokinase in acute cerebral infarction treatment.